

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 12/14/1976  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine**

ARUP test code 2007479

Creatinine, Urine 130.2 mg/dL (Ref Interval: 20.0-400.0)

Barbiturates Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Barbiturates Screen, U

Positive Cutoff: 200 ng/mL  
Methodology: Immunoassay

Cocaine Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Cocaine Screen, U

Positive Cutoff: 150 ng/mL  
Methodology: Immunoassay

Carisoprodol Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Carisoprodol Screen, U

Positive Cutoff: 100 ng/mL  
Methodology: Immunoassay

The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.

Ethyl Glucuronide Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: Ethyl Glucuronide Screen, U  
Positive Cutoff: 500 ng/mL  
Methodology: Immunoassay

**THC (Cannabinoids) Screen, U**

Presumptive POS  
Presumptive positive by immunoassay. Testing by mass spectrometry is available on request.  
INTERPRETIVE INFORMATION: THC (Cannabinoids) Screen, U  
Positive Cutoff: 50 ng/mL  
Methodology: Immunoassay

**Methadone Screen, U**

Negative  
Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.  
INTERPRETIVE INFORMATION: Methadone Screen, U  
Positive Cutoff: 150 ng/mL  
Methodology: Immunoassay

**Phencyclidine Screen, U**

Negative  
Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.  
INTERPRETIVE INFORMATION: Phencyclidine Screen, U  
Positive Cutoff: 25 ng/mL  
Methodology: Immunoassay

**Tramadol Screen, U**

Negative  
Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.  
INTERPRETIVE INFORMATION: Tramadol Screen, U  
Positive Cutoff: 100 ng/mL  
Methodology: Immunoassay

**6-acetylmorphine, U**

Not Detected  
INTERPRETIVE INFORMATION: 6-acetylmorphine, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

**7-Aminoclonazepam, U**

Not Detected  
INTERPRETIVE INFORMATION: 7-Aminoclonazepam, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

Alpha-OH-Alprazolam, U	Not Detected INTERPRETIVE INFORMATION:Alpha-OH-Alprazolam, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Alpha-OH-Midazolam, U	Not Detected INTERPRETIVE INFORMATION:Alpha-OH-Midazolam, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Alprazolam, U	Not Detected INTERPRETIVE INFORMATION:Alprazolam, U Positive Cutoff: 40 ng/mL Methodology: Mass Spectrometry
Amphetamine, U	Present INTERPRETIVE INFORMATION:Amphetamine, U Positive Cutoff: 50 ng/mL Methodology: Mass Spectrometry
Buprenorphine, U	Present INTERPRETIVE INFORMATION:Buprenorphine, U Positive Cutoff: 5 ng/mL Methodology: Mass Spectrometry
Clonazepam, U	Not Detected INTERPRETIVE INFORMATION:Clonazepam, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Codeine, U	Not Detected INTERPRETIVE INFORMATION: Codeine, U Positive Cutoff: 40 ng/mL Methodology: Mass Spectrometry
Diazepam, U	Not Detected INTERPRETIVE INFORMATION:Diazepam, U Positive Cutoff: 50 ng/mL Methodology: Mass Spectrometry
Fentanyl, U	Present INTERPRETIVE INFORMATION:Fentanyl, U Positive Cutoff: 2 ng/mL Methodology: Mass Spectrometry
Gabapentin, U	Not Detected

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION:Gabapentin, U  
Positive Cutoff: 3,000 ng/mL  
Methodology: Mass Spectrometry

Hydrocodone, U

Not Detected  
INTERPRETIVE INFORMATION:Hydrocodone, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

Hydromorphone, U

Not Detected  
INTERPRETIVE INFORMATION:Hydromorphone, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Lorazepam, U

Present  
INTERPRETIVE INFORMATION:Lorazepam, U  
Positive Cutoff: 60 ng/mL  
Methodology: Mass Spectrometry

MDA, U

Not Detected  
INTERPRETIVE INFORMATION:MDA, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

MDEA, U

Not Detected  
INTERPRETIVE INFORMATION:MDEA, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

MDMA, U

Not Detected  
INTERPRETIVE INFORMATION:MDMA, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

Meperidine metabolite, U

Not Detected  
INTERPRETIVE INFORMATION:Meperidine metabolite, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Methamphetamine, U

Present  
INTERPRETIVE INFORMATION:Methamphetamine, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

Methylphenidate, U

Not Detected

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION:Methylphenidate, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Midazolam, U

Not Detected  
INTERPRETIVE INFORMATION:Midazolam, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Morphine, U

Present  
INTERPRETIVE INFORMATION:Morphine, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Naloxone, U

Present  
INTERPRETIVE INFORMATION:Naloxone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Norbuprenorphine, U

Present  
INTERPRETIVE INFORMATION:Norbuprenorphine, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Nordiazepam, U

Not Detected  
INTERPRETIVE INFORMATION:Nordiazepam, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Norfentanyl, U

Present  
INTERPRETIVE INFORMATION:Norfentanyl, U  
Positive Cutoff: 2 ng/mL  
Methodology: Mass Spectrometry

Norhydrocodone, U

Not Detected  
INTERPRETIVE INFORMATION:Norhydrocodone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Noroxycodone, U

Not Detected  
INTERPRETIVE INFORMATION:Noroxycodone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Noroxymorphone, U

Not Detected

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION:Noroxymorphone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Oxazepam, U

Not Detected  
INTERPRETIVE INFORMATION:Oxazepam, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Oxycodone, U

Not Detected  
INTERPRETIVE INFORMATION:Oxycodone, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

Oxymorphone, U

Not Detected  
INTERPRETIVE INFORMATION:Oxymorphone, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

Phentermine, U

Not Detected  
INTERPRETIVE INFORMATION:Phentermine, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Pregabalin, U

Not Detected  
INTERPRETIVE INFORMATION:Pregabalin, U  
Positive Cutoff: 3,000 ng/mL  
Methodology: Mass Spectrometry

Tapentadol, U

Not Detected  
INTERPRETIVE INFORMATION:Tapentadol, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Tapentadol-o-Sulf, U

Not Detected  
INTERPRETIVE INFORMATION:Tapentadol-o-Sulf, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

Temazepam, U

Not Detected  
INTERPRETIVE INFORMATION:Temazepam, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Zolpidem, U

Not Detected

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION:Zolpidem, U

Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Zolpidem Metabolite, U

Not Detected

INTERPRETIVE INFORMATION:Zolpidem Metabolite, U

Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Targeted Drug Profile Comment

See Below

Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

EER Targeted Drug Profile, U

See Note

Authorized individuals can access the ARUP Enhanced Report using the following link:

[REDACTED LINK]

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Creatinine, Urine	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Barbiturates Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cocaine Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

Carisoprodol Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ethyl Glucuronide Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
THC (Cannabinoids) Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methadone Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Phencyclidine Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tramadol Screen, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
6-acetylmorphine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
7-Aminoclonazepam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alpha-OH-Alprazolam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alpha-OH-Midazolam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alprazolam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Amphetamine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Buprenorphine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Clonazepam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Codeine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Diazepam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Fentanyl, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Gabapentin, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hydrocodone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hydromorphone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Lorazepam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDA, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDEA, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDMA, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Meperidine metabolite, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methamphetamine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methylphenidate, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Midazolam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Morphine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Naloxone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norbuprenorphine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Nordiazepam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norfentanyl, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norhydrocodone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Noroxycodone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Noroxymorphone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxazepam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxycodone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxymorphone, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Phentermine, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pregabalin, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tapentadol, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-278-153808  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 8 of 9 | Printed: 1/18/2024 12:58:24 PM  
4848



Tapentadol-o-Sulf, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Temazepam, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zolpidem, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zolpidem Metabolite, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Targeted Drug Profile Comment	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER Targeted Drug Profile, U	23-278-153808	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

*Unless otherwise indicated, testing performed at:*

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-278-153808  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 9 of 9 | Printed: 1/18/2024 12:58:24 PM  
4848